Since we recently have established a cell based screening system, and identified a few natural compounds that upregulate endogenous Ngb expression, such as formononetin38, in future studies we may use these Ngb-upregulating compounds to treat animals at either acute phase of stroke to confer neuroprotection, or at recovery phase to promote neurogenesis. Here, NGB is linked to stroke disorder.